I N T R O D U C T I O N
Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Both the condition and its treatments are associated with considerable morbidity and mortality [1] with 33% of those with class IV disease reaching end-stage renal failure (ESRF) at 10 years [2] . However, earlier diagnosis and initiation of treatment are associated with better outcomes [3] . In this NDT Digest, we will discuss the classification of LN, the approaches to treatment based on guidelines and new evidence suggesting alternative strategies.
D I A G N O S I S O F L N
Clinical indicators for suspicion of renal injury in SLE are fairly uncontroversial: a reduction in renal function, new onset proteinuria of >50 mg/mmol or a doubling of 'baseline' proteinuria to >100 mg/mmol and/or an active urine sediment. Renal biopsy is required to classify the LN histologically as this influences both the treatment and prognosis. A practical guide to the International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of LN is displayed in Figure 1 : it is class III or IV if there are active or sclerotic glomerular lesions with endocapillary hypercellularity, subendothelial deposits [wire-loops on light microscopy and seen on electron microscopy (EM)], intraluminal immune aggregates (hyaline thrombi) or crescents, among other features. Immunofluorescence typically shows 'full house' deposition of immunoglobulins and complement. The nephritis is considered class III where these changes are present in <50% of glomeruli or class IV if in >50%. The activity of the glomerular lesions is also classified (all active, active/chronic or all chronic). For those with class IV, the glomerular lesions are further described as predominantly segmental (S), if most glomeruli have <50% tuft involved, or global (G).
Class V LN involves membranous change, with 'full house' granular immunofluorescence and subepithelial immune deposits on EM. Class III/IV LN can coexist with class V.
If the biopsy shows only mesangial hypercellularity then it is class II. These patients are likely to have minimal proteinuria and normal function. In class I LN, there are immune complexes detected by immunofluorescence or EM alone.
It is worth remembering that the classification of LN refers only to glomerular changes that are a consequence of immune complex deposition. Other manifestations can however be found, including tubulointerstitial inflammation, and vasculopathy and/ or thrombotic microangiopathy (usually in association with antiphospholipid antibodies) [5] . The degree of tubulointerstitial scarring is also prognostic and should be documented.
The treatment of proliferative LN is generally divided into induction and maintenance phases. Induction with intravenous (IV) cyclophosphamide (CyP) or mycophenolate mofetil (MMF) (target 2-3 g daily) is recommended alongside corticosteroids (IV then oral) [6] , the dose and duration of which are based on expert opinion rather than trial data. Wherever higher and lower doses of steroids have been compared, lower doses are associated with just as good or better outcomes and fewer side-effects. We recommend methylprednisolone IV pulses of no more than 500 mg each and for oral steroids, a low starting dose (40 mg/day, max. 0.5 mg/kg/day) with rapid taperthese strategies are effective and safer [7] . Preliminary results from the AURA LN trial [8] , which added voclosporin or placebo to MMF and rapidly tapered steroids, have been released. Not only did the trial reach its endpoint, the control data are also of great interest, showing similar or higher remission rates than previous studies despite much lower doses of steroids used with MMF. CyP (as per either the Eurolupus or NIH regimens) and MMF have similar efficacy; however, CyP may reduce fertility, though this is less likely with low dose regimens. Maintenance treatment is recommended with MMF (1-2 g/day) or azathioprine (1.5-2.5 mg/kg/day) alongside low-dose corticosteroids for at least 1 (KDIGO) to 3 (EULAR/ERA-EDTA) years following complete remission [6] .
Treatment of pure class V is more controversial due to less robust evidence. It is worth noting that while prognosis is more benign, a significant proportion of patients reach ESRF by 10 years [2] . It is usually treated the same as class III or IV LN. Most guidelines agree that nephrotic-range proteinuria (>3 g/ 24 h or urine protein:creatinine ratio >300 mg/mmol) warrants immunosuppressive treatment [6] .
A significant proportion of patients do not respond to treatment. It is recommended with refractory disease to switch therapy from MMF to CyP or vice versa [6] . With relapsing disease it is advised to repeat the treatment that was effective at bringing about remission. In both scenarios, a repeat renal biopsy should be considered as the pathogenic manifestations can change and may indicate alternative treatment.
We are now 5 years on from the guidelines discussed above and usefully compared by Wilhelmus et al. [6] . While they still represent the standard of care, almost none of the treatments described are licensed for use and there have been developments, including emerging roles for both biologics and multitarget therapy. Multi-target refers to the combination of lowdose steroid, MMF and a calcineurin inhibitor (CNI); both the AURA trial [8] and a large phase III study from China [9] have demonstrated superiority of such a combination as induction treatment in comparison with standard of care. Disappointingly, the role of rituximab is yet to be defined by positive trial data though it is widely used (and indeed approved by NHS England) for refractory LN, while cohort data suggest it shows benefit as primary therapy [10] . Several randomized trials in LN are ongoing, using drugs aimed at key biological pathways including an anti-interferon receptor blocker, anifrolumab (NCT02547922), an anti-CD40L antibody (NCT00001789) and the anti-BAFF antibody, belimumab (NCT01639339).
There is very little evidence or agreement among guidelines in regards to treatment of class II LN except for the use of renin-angiotensin-aldosterone system (RAAS) inhibitors. Immunosuppression is largely directed towards extrarenal manifestations. Class I LN requires no specific therapy as it has no clinical manifestations and is not associated with long-term renal impairment [11] .
A D J U N C T I V E T R E A T M E N T S I N L N
Various adjunctive treatments are advised by the majority of guidelines, particularly the use of hydroxychloroquine [6] , which is associated with sustained remission [12] and a reduced rate of relapse [13] . Screening with an ophthalmologist for retinopathy at baseline and yearly after 5 years is recommended [6] . RAAS inhibition for proteinuria and blood pressure control and statins for hyperlipidaemia are consistently recommended, as are consideration of calcium and vitamin D supplements, bisphosphonates, low-dose aspirin, anticoagulation in those with albumin <20 g/L, ovarian protection with GnRH analogues if cumulative CyP dose >10 g and avoidance of live vaccines [6] . In addition, low-dose prophylactic antibiotics can be considered while complement levels are low. Contraception is warranted for all patients on MMF or CyP and pregnancy should be avoided until remission is sustained for at least 6 months. 
C O N C L U S I O N S
With current advances in personalized medicine, we may see a change in approach to treatment in the coming years with therapeutics tailored to specific pathogenic mechanisms of injury identified by 'omics analysis of biopsies, blood and/or urine'. Until then, and awaiting new data from the many trials, MMF or CyP remain the standard of care, with growing support for the use of CNI inhibition.
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